 |
0 Diseases |  |
10 Trials |
|
10 Trials |  |
233 News |  |
| «12345 |
- ||| zanidatamab (ZW25) / Zymeworks, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, DZD1516 / Dizal Pharma
Clinical: (I was on ds8201a w/nivolamab). Now on plain Enhertu. Did ZW25 a couple yrs back. Now info gathering on DZD1516 (oral single agent and 👍🏻#cns #lmd #bcbm) just in case 🤷🏻♀️ (Twitter) - Sep 20, 2020
- || Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Aug 27, 2020
P1, N=234, Recruiting, Sponsor: Zymeworks Inc.
Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Jan 2022
- || Ziihera (zanidatamab-hrii) / Jazz
New P2 trial: ZW25-IST-2: ZW25 in Women With Endometrial Cancers (clinicaltrials.gov) - Aug 13, 2020
P2, N=25, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Aug 12, 2020
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Jan 2022 Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021
- |||| Clinical: So great that HER2+ GEA has many promising new tx’s! The next yrs will be important for us to study how to optimally sequence of all of them to best treat our pts!! #margetuximab #tras #tucatinib #trasderux #zw25 etc... #retifanlimab #pembro #nivo etc... https://t.co/pV9nE4SrVh (Twitter) - Jul 10, 2020
- ||||| Ziihera (zanidatamab-hrii) / Jazz
New P2b trial, Monotherapy, Metastases: HERIZON-BTC-01: A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (clinicaltrials.gov) - Jul 9, 2020
P2b, N=100, Recruiting, Sponsor: Zymeworks Inc.
- | ZW25 / Zymeworks
Journal: Subcellular location prediction of apoptosis proteins using two novel feature extraction methods based on evolutionary information and LDA. (Pubmed Central) - Jun 28, 2020
Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021 The experimental results show that the proposed method which is hopefully to be a complementary tool for the existing methods of subcellular localization, can effectively extract more abundant features of protein sequence and is feasible in predicting the subcellular location of apoptosis proteins.
- | ZW25 / Zymeworks
Journal: Prediction of apoptosis protein subcellular location based on position-specific scoring matrix and isometric mapping algorithm. (Pubmed Central) - May 1, 2020
The experimental results show that the proposed method not only extracts more abundant feature expression but also has better predictive performance and robustness for the subcellular localization of apoptosis proteins in ZD98, ZW225, and CL317 databases. Graphical abstract Framework of the proposed prediction model.
- Baize’an (tislelizumab) / BeiGene, BMS, ZW25 / Zymeworks
[VIRTUAL] ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. (Poster Board 209) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1416;
In cohort 2, treatment-naïve pts with HER2-positive (IHC3+ or IHC2+ with ISH amplification) advanced GC/GEJC will receive ZW25 30 mg/kg plus tislelizumab 200 mg IV and chemotherapy (CAPOX regimen: capecitabine 1000 mg/m2 twice daily and oxaliplatin 130 mg/m2 IV) Q3W...Primary endpoints are the safety/tolerability profile and objective response rate; secondary endpoints include duration of response, time to response, progression-free survival, disease control rate, and overall survival. Research Funding: BeiGene, Ltd.
- || Tevimbra (tislelizumab-jsgr) / BeiGene, Ziihera (zanidatamab-hrii) / Jazz
Enrollment open, Combination therapy, Metastases: BGB-A317-ZW25-101: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab (clinicaltrials.gov) - Apr 9, 2020
P1b/2, N=50, Recruiting, Sponsor: BeiGene
Research Funding: BeiGene, Ltd. Not yet recruiting --> Recruiting
- || Ziihera (zanidatamab-hrii) / Jazz
Trial initiation date, Combination therapy, Metastases: ZWI-ZW25-202: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer (clinicaltrials.gov) - Mar 31, 2020
P2a, N=76, Recruiting, Sponsor: Zymeworks Inc.
Not yet recruiting --> Recruiting Initiation date: Jan 2020 --> Apr 2020
- | Biomarker, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=4000, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Initiation date: Jan 2020 --> Apr 2020 N=1920 --> 4000
- ||| ZW25 / Zymeworks, A166 / Sichuan Kelun Pharma
@pashtoonkasi Did this pt have successful treatment after My Pathway? My husband is ERBB2 amplified, but progressed on ZW25 and A166. (Twitter) - Feb 4, 2020
- ||| ZW25 / Zymeworks, A166 / Sichuan Kelun Pharma
Did this pt have successful treatment after My Pathway? My husband is ERBB2 amplified, but progressed on ZW25 and A166. (Twitter) - Feb 4, 2020
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jan 22, 2020
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=1920 --> 4000 Trial primary completion date: Dec 2020 --> Dec 2025
- |||| Ziihera (zanidatamab-hrii) / Jazz
New P2a trial, Combination therapy, Metastases: ZWI-ZW25-202: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer (clinicaltrials.gov) - Jan 13, 2020
P2a, N=76, Recruiting, Sponsor: Zymeworks Inc.
- |||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Enrollment open, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Dec 23, 2019
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Trial primary completion date: Dec 2020 --> Dec 2025 Not yet recruiting --> Enrolling by invitation
- || Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Dec 17, 2019
P1, N=234, Recruiting, Sponsor: Zymeworks Inc.
Not yet recruiting --> Enrolling by invitation Trial completion date: Dec 2019 --> Oct 2020 | Trial primary completion date: Dec 2019 --> Sep 2020
- | ZW25 / Zymeworks
Journal: Prediction of Protein Subcellular Localization Based on Fusion of Multi-view Features. (Pubmed Central) - Nov 29, 2019
Even without using machine learning-based classifiers, a simple model based on the feature vector can achieve prediction accuracies of 0.8825 and 0.7736 respectively for the CL317 and ZW225 datasets...The results suggest that the GCGR and NSI features are useful complements to popular protein sequence representations in predicting yeast protein subcellular localization. Finally, we validate a few newly predicted protein subcellular localizations by evidences from some published articles in authority journals and books.
- | ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
ZW25 binding 2 HER2 epitopes: ECD4, the trastuzumab binding domain, and ECD2, the pertuzumab binding domain. (Twitter) - Nov 22, 2019
- || ZW25 / Zymeworks
Updated #ZW25 Data in HER2-expressing #Cancers to be Presented by Dr. Do-Youn Oh of Seoul National University at #ESMOAsia19 on Friday 11/22 at 3:30pm SGT in Room 311 $ZYME (Twitter) - Nov 21, 2019
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
New P3 trial, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Nov 15, 2019
P3, N=300, Not yet recruiting, Sponsor: BeiGene
- | ZW25 / Zymeworks
Journal: Predicting apoptosis protein subcellular localization by integrating auto-cross correlation and PSSM into Chou's PseAAC. (Pubmed Central) - Nov 14, 2019
Our model achieves competitive performance on prediction accuracies, especially for the overall prediction accuracies for datasets ZW225 and CL317, which reach 84.9% and 90.5%, respectively. Comparison of our results with other methods demonstrates that MACC-PSSM model can be used as a potential candidate for the accurate prediction of apoptosis protein subcellular localization.
- || ZW25 / Zymeworks
$ZYME ZW25+ Chemo Combo in HER2 expressing GEA (median 3 of prior anti-cancer regimens): 63 % ORR and 27 % AE ≥ 3 . For comparison: $AZN T-Dxd: 43 % ORR and 47 % AE ≥ 3. #AACR2019 (Twitter) - Oct 17, 2019
- || ZW25 / Zymeworks
Still think that inserting ZW25 in place of tras will achieve even better results in this setting and every setting where tras is used alone or in combo - but in the absence of pertuz - (Twitter) - Sep 29, 2019
- || ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche
All these response numbers would be even better, w/ no increase in AE's, if you substituted ZW25 for trastuzumab. (Twitter) - Sep 28, 2019
- ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg.
Safety and efficacy of ZW25, a HER2‑targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer (Board 1: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_222;
P1, P2
Patients received ZW25 in combination with paclitaxel or capecitabine...This patient had been previously treated with trastuzumab, cisplatin, and capecitabine; pembrolizumab and margetuximab; and most recently DS8201, and had asymptomatic interstitial lung disease at study entry...Conclusions The combination of ZW25 with chemotherapy was generally well tolerated in heavily pre-treated patients with HER2 high- and low-expressing GEA and the preliminary anti-tumor activity is promising. Further evaluation of the safety and efficacy of ZW25 in combination with standard of care chemotherapy regimens has been initiated in frontline GEA (ZW25-201; NCT03929666).
- ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche
Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours (Room 311) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_288;
P1
These data support further clinical development of this bispecific antibody in HER2-expressing solid tumors.Legal entity responsible for the study: Zymeworks Inc. Funding: Zymeworks Inc.
- ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche
Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours (Alicante Auditorium (Hall 3)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3172;
P2
These data support further clinical development of this bispecific antibody in HER2-expressing solid tumors. Clinical trial identification: NCT03929666.
- | Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Aug 29, 2019
P2, N=115, Recruiting, Sponsor: Zymeworks Inc.
Clinical trial identification: NCT03929666. Trial completion date: Oct 2023 --> Jan 2023 | Trial primary completion date: Oct 2021 --> Feb 2022
- || Ziihera (zanidatamab-hrii) / Jazz
Enrollment change, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Jun 20, 2019
P1, N=234, Recruiting, Sponsor: Zymeworks Inc.
Trial completion date: Oct 2023 --> Jan 2023 | Trial primary completion date: Oct 2021 --> Feb 2022 N=150 --> 234
- || ZW25 / Zymeworks, ZW49 / Zymeworks
Preclinical: The ADC version of ZW25 - ZW49 - is entering the clinic now. Preclinical data were impressive (large therapeutic window & tumor regression) with the usual grain of salt. (Twitter) - Jun 4, 2019
- | ZW25 / Zymeworks, Herceptin (trastuzumab) / Roche
Ah, the "better Herceptin" for people who are unfamiliar with $ZYME ZW25. (Twitter) - Jun 4, 2019
- | ZW25 / Zymeworks, [fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo
You literally asked me to clarify. At the end of the day where does marge fit with zw25 and ds-8201 in the pipeline anyway? (Twitter) - May 16, 2019
- | ZW25 / Zymeworks, ZW49 / Zymeworks
2 missing from the list are $ZYME bispecific anti-HER2 mAb ZW25 in ph2 and bispecific anti-HER2 mAb ADC ZW49 in ph1 https://t.co/ozdDsGn9Wc https://t.co/kUTt4EorcC (Twitter) - May 8, 2019
- || ZW25 / Zymeworks, [fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo
I know it's a crowded field, but might toss in Pieris (4-1BB x HER2; cool MOA) and ZW25 (better PFS to DS8201 but as unconjugated (lytic) mAb in GEA) (Twitter) - May 8, 2019
- |||| Ziihera (zanidatamab-hrii) / Jazz
New P2 trial: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2019
P2, N=91, Recruiting, Sponsor: Zymeworks Inc.
- | Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Sep 14, 2018
P1, N=150, Recruiting, Sponsor: Zymeworks Inc.
N=150 --> 234 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- || Ziihera (zanidatamab-hrii) / Jazz
Enrollment change, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Apr 27, 2018
P1, N=150, Recruiting, Sponsor: Zymeworks Inc.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 N=99 --> 150
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 20, 2017
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=99 --> 150 Trial primary completion date: Dec 2018 --> Dec 2020
- || Ziihera (zanidatamab-hrii) / Jazz
Enrollment change, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Aug 16, 2017
P1, N=99, Recruiting, Sponsor: Zymeworks Inc.
Trial primary completion date: Dec 2018 --> Dec 2020 N=30 --> 99
- Ziihera (zanidatamab-hrii) / Jazz
Trial primary completion date, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Mar 24, 2017
P1, N=30, Recruiting, Sponsor: Zymeworks Inc.
N=30 --> 99 Trial primary completion date: Aug 2018 --> Dec 2018
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Aug 2018 --> Dec 2018 Trial primary completion date: May 2018 --> Dec 2018
- Ziihera (zanidatamab-hrii) / Jazz
New P1 trial, Metastases: ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov) - Sep 8, 2016
P1, N=30, Recruiting, Sponsor: Zymeworks Inc.
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: May 2018 --> Dec 2018 N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Trial primary completion date: Feb 2014 --> Sep 2015